Progeria Clinical Trial
Official title:
A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
This is an open label single arm feasibility trial. A combination of two oral agents (pravastatin and lonafarnib) and one intravenous (IV) agent (zoledronic acid) will be administered at doses and schedule currently applied in pediatrics. These agents all target farnesylation pathways at different points. Our goal is to inhibit farnesylation of abnormal lamin, the disease-causing protein in Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies (henceforth "progeria"). The drugs will include the intravenous bisphosphonate zoledronic acid, oral HMG co-reductase inhibitor pravastatin and the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH 66336). Patients with genetically confirmed progeria will be eligible for this protocol. Treatment will be initiated for 4 weeks duration and may be extended depending on tolerability. This study will assess the feasibility of this treatment regimen in the first 4 weeks. If tolerated for 4 weeks, patients can be treated with this regimen for up to 6 months.
Progerias are rare "premature aging" diseases in which children die of severe atherosclerosis
leading to strokes and heart attacks. It is a multisystem disease with objective clinical
markers for disease progression. These include abnormalities in growth and body composition,
bone mineral density, join function, endocrine function, alopecia, and vascular disease.
There is currently no therapy proven effective for any of the progressive and deleterious
aspects of this disorder.
Progeria is caused by a gene defect in the gene LMNA, coding for the nuclear protein lamin A.
Lamin A is normally expressed by most differentiated cells, and requires posttranslational
farnesylation to incorporate into the nuclear membrane. This trial proposes to use three
agents (zoledronic acid, pravastatin, and lonafarnib) to inhibit farnesylation of abnormal
lamin, the disease causing protein in Progeria. The primary objective of this study is to
evaluate the feasibility of administering intravenous zoledronic acid, oral pravastatin and
oral lonafarnib, to patients wtih Progeria for a minimum of 4 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00094393 -
Clinical Studies of Progeria
|
||
Completed |
NCT00425607 -
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
|
Phase 2 | |
Enrolling by invitation |
NCT02579044 -
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00916747 -
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
|
Phase 2 | |
Approved for marketing |
NCT03895528 -
Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
|